PortfoliosLab logoPortfoliosLab logo
URGN vs. ICE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

URGN vs. ICE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in UroGen Pharma Ltd. (URGN) and Intercontinental Exchange, Inc. (ICE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, URGN achieves a 63.28% return, which is significantly higher than ICE's -5.20% return.


URGN

1D
-6.94%
1M
0.58%
6M
95.00%
YTD
63.28%
1Y
97.11%
3Y*
23.50%
5Y*
19.79%
10Y*
ALL TIME*
12.12%

ICE

1D
-2.43%
1M
14.66%
6M
-11.65%
YTD
-5.20%
1Y
-16.34%
3Y*
11.23%
5Y*
6.32%
10Y*
12.62%
ALL TIME*
16.35%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$688.42M$623.20M$636.51M
$24.52M$29.78M$26.02M

URGN vs. ICE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
URGN
UroGen Pharma Ltd.
63.28%119.91%-29.00%69.11%-6.73%-47.23%-46.00%-22.50%15.72%179.98%
ICE
Intercontinental Exchange, Inc.
-5.20%9.92%17.46%27.12%-23.91%19.94%26.15%24.47%8.11%18.01%

Correlation

The correlation between URGN and ICE is 0.12, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.12

Correlation (3Y)
Balances recent behavior with more history.

0.13

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.15

Correlation (All Time)
Calculated using the full available price history since May 4, 2017

0.16

Fundamentals

Market Cap

URGN:

$1.86B

ICE:

$85.99B

EPS

URGN:

-$2.71

ICE:

$7.06

PS Ratio

URGN:

13.38

ICE:

6.48

Total Revenue (TTM)

URGN:

$140.49M

ICE:

$13.42B

Gross Profit (TTM)

URGN:

$126.24M

ICE:

$10.01B

EBITDA (TTM)

URGN:

-$117.04M

ICE:

$6.36B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

URGN vs. ICE — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

URGN
URGN Risk / Return Rank: 8282
Overall Rank
URGN Sharpe Ratio Rank: 8686
Sharpe Ratio Rank
URGN Sortino Ratio Rank: 8383
Sortino Ratio Rank
URGN Omega Ratio Rank: 8080
Omega Ratio Rank
URGN Calmar Ratio Rank: 8282
Calmar Ratio Rank
URGN Martin Ratio Rank: 7979
Martin Ratio Rank

ICE
ICE Risk / Return Rank: 1919
Overall Rank
ICE Sharpe Ratio Rank: 1414
Sharpe Ratio Rank
ICE Sortino Ratio Rank: 1616
Sortino Ratio Rank
ICE Omega Ratio Rank: 1616
Omega Ratio Rank
ICE Calmar Ratio Rank: 2727
Calmar Ratio Rank
ICE Martin Ratio Rank: 2323
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

URGN vs. ICE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Intercontinental Exchange, Inc. (ICE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


URGNICEDifference
Sharpe ratioReturn per unit of total volatility

+2.21

Sortino ratioReturn per unit of downside risk

+3.04

Omega ratioGain probability vs. loss probability

1.27

0.90

+0.37

Calmar ratioReturn relative to maximum drawdown

2.40

-0.49

+2.88

Martin ratioReturn relative to average drawdown

4.98

-0.99

+5.96

URGN vs. ICE - Sharpe Ratio Comparison

The current URGN Sharpe Ratio is 1.54, which is higher than the ICE Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of URGN and ICE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

URGN vs. ICE - Drawdown Comparison

The maximum URGN drawdown since its inception was -93.98%, which is greater than ICE's maximum drawdown of -73.94%. Use the drawdown chart below to compare losses from any high point for URGN and ICE.


Loading charts...

Drawdown Indicators


URGNICEDifference

Max Drawdown

Largest peak-to-trough decline

-93.98%

-73.94%

-20.04%

Max Drawdown (1Y)

Largest decline over 1 year

-42.22%

-33.94%

-8.28%

Max Drawdown (3Y)

Largest decline over 3 years

-82.64%

-33.94%

-48.70%

Max Drawdown (5Y)

Largest decline over 5 years

-82.64%

-34.32%

-48.32%

Max Drawdown (10Y)

Largest decline over 10 years

-34.32%

Current Drawdown

Current decline from peak

-41.47%

-18.05%

-23.42%

Average Drawdown

Average peak-to-trough decline

-61.22%

-16.52%

-44.70%

Ulcer Index

Depth and duration of drawdowns from previous peaks

20.29%

16.71%

+3.58%

Volatility

URGN vs. ICE - Volatility Comparison

UroGen Pharma Ltd. (URGN) has a higher volatility of 14.36% compared to Intercontinental Exchange, Inc. (ICE) at 7.90%. This indicates that URGN's price experiences larger fluctuations and is considered to be riskier than ICE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


URGNICEDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.36%

7.90%

+6.46%

Volatility (6M)

Calculated over the trailing 6-month period

41.70%

20.61%

+21.09%

Volatility (1Y)

Calculated over the trailing 1-year period

65.71%

24.53%

+41.18%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.70%

21.65%

+70.05%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

79.11%

22.42%

+56.69%

Dividends

URGN vs. ICE - Dividend Comparison

URGN has not paid dividends to shareholders, while ICE's dividend yield for the trailing twelve months is around 1.31%.


PositionTTM20252024202320222021202020192018201720162015
ICE
Intercontinental Exchange, Inc.
1.31%1.19%1.21%1.31%1.48%0.97%1.04%1.19%1.27%1.13%1.21%1.13%
URGN
UroGen Pharma Ltd.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

URGN vs. ICE - Financials Comparison

This section allows you to compare key financial metrics between UroGen Pharma Ltd. and Intercontinental Exchange, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

URGN vs. ICE - Profitability Comparison

The chart below illustrates the profitability comparison between UroGen Pharma Ltd. and Intercontinental Exchange, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

URGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported a gross profit of 46.82M and revenue of 50.96M. Therefore, the gross margin over that period was 91.9%.

ICE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Intercontinental Exchange, Inc. reported a gross profit of 2.82B and revenue of 3.61B. Therefore, the gross margin over that period was 78.2%.

URGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported an operating income of -20.26M and revenue of 50.96M, resulting in an operating margin of -39.8%.

ICE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Intercontinental Exchange, Inc. reported an operating income of 1.39B and revenue of 3.61B, resulting in an operating margin of 38.5%.

URGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, UroGen Pharma Ltd. reported a net income of -23.57M and revenue of 50.96M, resulting in a net margin of -46.3%.

ICE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Intercontinental Exchange, Inc. reported a net income of 958.00M and revenue of 3.61B, resulting in a net margin of 26.5%.


Frequently Asked Questions


URGN and ICE have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

URGN has higher volatility (14.36%) compared to ICE (7.90%). In terms of maximum drawdown, URGN dropped -93.98% vs ICE's -73.94%.

URGN currently has the higher Sharpe Ratio (1.54 vs -0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for URGN and ICE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer